{"id":"NCT03964415","sponsor":"Janssen Vaccines & Prevention B.V.","briefTitle":"A Study of Heterologous Vaccine Regimen of Adenovirus Serotype 26 Mosaic4 Human Immunodeficiency Virus(Ad26.Mos4.HIV), Adjuvanted Clade C gp140 and Mosaic gp140 to Prevent HIV-1 Infection Among Cis-gender Men and Transgender Individuals Who Have Sex With Cis-gender Men and/or Transgender Individuals","officialTitle":"A Multi-center, Randomized, Double-blind, Placebo-controlled Phase 3 Efficacy Study of a Heterologous Vaccine Regimen of Ad26.Mos4.HIV and Adjuvanted Clade C gp140 and Mosaic gp140 to Prevent HIV-1 Infection Among Cis-gender Men and Transgender Individuals Who Have Sex With Cis-gender Men and/or Transgender Individuals","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2019-10-31","primaryCompletion":"2023-08-10","completion":"2023-08-10","firstPosted":"2019-05-28","resultsPosted":"2024-07-31","lastUpdate":"2024-07-31"},"enrollment":3900,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"PREVENTION"},"conditions":["Healthy"],"interventions":[{"type":"BIOLOGICAL","name":"Ad26.Mos4.HIV","otherNames":[]},{"type":"BIOLOGICAL","name":"Clade C and Mosaic gp140 HIV bivalent vaccine","otherNames":[]},{"type":"BIOLOGICAL","name":"Placebo","otherNames":[]}],"arms":[{"label":"Group1:Ad26.Mos4.HIV,Clade C and Mosaic gp140 bivalent vaccine","type":"EXPERIMENTAL"},{"label":"Group 2: Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to evaluate the vaccine efficacy (VE) of a heterologous vaccine regimen utilizing Ad26.Mos4.HIV and aluminum phosphate-adjuvanted Clade C gp140 and Mosaic gp140 for the prevention of HIV-1 infection in HIV-1 seronegative cis-gender men and transgender individuals having sex with cis-gender men and/or transgender individuals.","primaryOutcome":{"measure":"Number of Participants With Confirmed Human Immunodeficiency Virus (HIV)-1 Infections Diagnosed Between the Month 7 and Month 24 Visits (Per-protocol [PP] Set)","timeFrame":"From Month 7 up to Month 24","effectByArm":[{"arm":"Group 1: Ad26.Mos4.HIV + Clade C and Mosaic gp140","deltaMin":65,"sd":null},{"arm":"Group 2: Placebo","deltaMin":58,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":true,"inclusionCount":5,"exclusionCount":5},"locations":{"siteCount":53,"countries":["United States","Argentina","Brazil","Italy","Mexico","Peru","Poland","Puerto Rico","Spain"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":82,"n":1942},"commonTop":["Fatigue (Solicited)","Vaccination Site Pain (Solicited)","Headache (Solicited)","Myalgia (Solicited)","Chills (Solicited)"]}}